Heron Therapeutics, Inc.
HRTX
$2.48
$0.093.77%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 87.72% | 76.64% | 64.77% | 46.36% | 39.26% |
| Total Depreciation and Amortization | -14.04% | -11.73% | -6.16% | -0.55% | 0.35% |
| Total Amortization of Deferred Charges | 183.48% | 264.60% | 153.66% | 110.84% | 67.82% |
| Total Other Non-Cash Items | -52.11% | -54.89% | -51.39% | -30.70% | -25.36% |
| Change in Net Operating Assets | -264.40% | 95.74% | 109.62% | 137.93% | 259.81% |
| Cash from Operations | 61.68% | 91.60% | 83.54% | 66.06% | 59.98% |
| Capital Expenditure | -10.42% | 22.88% | -74.82% | -31.44% | 15.34% |
| Sale of Property, Plant, and Equipment | 107.69% | 333.33% | -92.40% | -92.40% | -94.27% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 4.43% | -100.77% | -260.94% | -169.46% | 1,231.34% |
| Cash from Investing | 4.00% | -105.34% | -279.28% | -177.83% | 641.37% |
| Total Debt Issued | -- | -100.00% | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -96.93% | -97.69% | -60.20% | -59.97% | -59.97% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | 99.82% | 69.87% | 37.87% | 40.98% |
| Cash from Financing | -98.26% | -98.68% | -27.81% | -28.03% | -27.91% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -121.60% | 41.47% | 114.01% | 77.73% | 117.71% |
